Approved CAR-T therapies have reproducible efficacy and safety in clinical practice.
Hum Vaccin Immunother
; 20(1): 2378543, 2024 Dec 31.
Article
en En
| MEDLINE
| ID: mdl-39104200
ABSTRACT
CAR-T cell therapy has established itself as a highly effective treatment for hematological malignancies. There are currently six commercial CAR-T products that have been FDA approved for diseases such as B-ALL, LBCL, MCL, FL, MM, and CLL/SLL. "Real-world" studies allow us to evaluate outcomes from the general population to determine their efficacy and safety compared to those who were included in the original trials. Based on several well conducted "Real-world" studies that represent diverse populations, we report that outcomes from the original trials that led to the approval of these therapies are comparable to those in practice.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Inmunoterapia Adoptiva
/
Neoplasias Hematológicas
/
Receptores Quiméricos de Antígenos
Límite:
Humans
Idioma:
En
Revista:
Hum Vaccin Immunother
Año:
2024
Tipo del documento:
Article
País de afiliación:
Estados Unidos
Pais de publicación:
Estados Unidos